Oral oncolytics: assessing value of newer agents versus current standards of care as part of PT processes
Oral oncolytics are relatively new to the field of cancer therapy. They currently make up about 25% of the oncology market and their use is continually expanding. The current insurance system is not efficiently equipped to handle the rapid expansion of oral oncolytics into the market, and the curren...
Gespeichert in:
| Veröffentlicht in: | Formulary (Cleveland, Ohio) Ohio), 2013-08, Vol.48 (8), p.258 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 258 |
| container_title | Formulary (Cleveland, Ohio) |
| container_volume | 48 |
| creator | Weaver, Salome Bwayo Moore, Clarence Shah, Vicky Serlemitsos-Day, Maritsa |
| description | Oral oncolytics are relatively new to the field of cancer therapy. They currently make up about 25% of the oncology market and their use is continually expanding. The current insurance system is not efficiently equipped to handle the rapid expansion of oral oncolytics into the market, and the current insurance benefit design contributes significantly to access issues for patients. This article offers formulary decision makers information needed to evaluate newer oral oncolytic therapies compared with existing standards of care using guidelines from the National Comprehensive Cancer Network®. The oral agents discussed are limited to those introduced into the market since 2007. [PUBLICATION ABSTRACT] |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1430341971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A343462272</galeid><sourcerecordid>A343462272</sourcerecordid><originalsourceid>FETCH-LOGICAL-g288t-e2d8a48151306d2aa6770e474999ea0bf5c98025aecd198ddec5f749f7e50a073</originalsourceid><addsrcrecordid>eNptkE1Lw0AQhoMoWKv_YcFzZL-SbLyV4hcU9FDBWxh3JyEl3dSdTcV_7xYFEcocZt6ZZ96BOclmolYmF6IsT1PNjcwNF2_n2QXRhnNelkrOsv45wMBGb8fhK_aWbhkQIVHvO7aHYUI2tszjJwYGHfpIbI-BJmJ2CiFpRhG8g-DoAFoImAzYDkI86Jc124XR4sHyMjtrYSC8-s3z7PX-br18zFfPD0_LxSrvpDExR-kMaCMKoXjpJEBZVRx1peu6RuDvbWFrw2UBaJ2ojXNoizZN2woLDrxS8-z6xzdd_piQYrMZp-DTyUZoxZUWdSX-qA4GbHrfjjGA3fZkm4XSSpdSVjJR-REq_QHT10aPbZ_a__ibI3wKh9veHln4Bi7igFc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1430341971</pqid></control><display><type>article</type><title>Oral oncolytics: assessing value of newer agents versus current standards of care as part of PT processes</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Business Source Complete</source><creator>Weaver, Salome Bwayo ; Moore, Clarence ; Shah, Vicky ; Serlemitsos-Day, Maritsa</creator><creatorcontrib>Weaver, Salome Bwayo ; Moore, Clarence ; Shah, Vicky ; Serlemitsos-Day, Maritsa</creatorcontrib><description>Oral oncolytics are relatively new to the field of cancer therapy. They currently make up about 25% of the oncology market and their use is continually expanding. The current insurance system is not efficiently equipped to handle the rapid expansion of oral oncolytics into the market, and the current insurance benefit design contributes significantly to access issues for patients. This article offers formulary decision makers information needed to evaluate newer oral oncolytic therapies compared with existing standards of care using guidelines from the National Comprehensive Cancer Network®. The oral agents discussed are limited to those introduced into the market since 2007. [PUBLICATION ABSTRACT]</description><identifier>ISSN: 1082-801X</identifier><identifier>EISSN: 1938-1166</identifier><language>eng</language><publisher>North Olmsted: Intellisphere, LLC</publisher><subject>Anemia ; Antimitotic agents ; Antineoplastic agents ; Blood platelets ; Cancer ; Cancer therapies ; Chromosomes ; Drug dosages ; Drug stores ; Health aspects ; Kinases ; Leukemia ; Medical treatment ; Medicare ; Mutation ; Neutropenia ; Oncology ; Patients ; Pharmacy ; Physicians ; Prescription drugs ; Thrombocytopenia</subject><ispartof>Formulary (Cleveland, Ohio), 2013-08, Vol.48 (8), p.258</ispartof><rights>COPYRIGHT 2013 Intellisphere, LLC</rights><rights>Copyright Advanstar Communications, Inc. Aug 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Weaver, Salome Bwayo</creatorcontrib><creatorcontrib>Moore, Clarence</creatorcontrib><creatorcontrib>Shah, Vicky</creatorcontrib><creatorcontrib>Serlemitsos-Day, Maritsa</creatorcontrib><title>Oral oncolytics: assessing value of newer agents versus current standards of care as part of PT processes</title><title>Formulary (Cleveland, Ohio)</title><description>Oral oncolytics are relatively new to the field of cancer therapy. They currently make up about 25% of the oncology market and their use is continually expanding. The current insurance system is not efficiently equipped to handle the rapid expansion of oral oncolytics into the market, and the current insurance benefit design contributes significantly to access issues for patients. This article offers formulary decision makers information needed to evaluate newer oral oncolytic therapies compared with existing standards of care using guidelines from the National Comprehensive Cancer Network®. The oral agents discussed are limited to those introduced into the market since 2007. [PUBLICATION ABSTRACT]</description><subject>Anemia</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Blood platelets</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chromosomes</subject><subject>Drug dosages</subject><subject>Drug stores</subject><subject>Health aspects</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Medical treatment</subject><subject>Medicare</subject><subject>Mutation</subject><subject>Neutropenia</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pharmacy</subject><subject>Physicians</subject><subject>Prescription drugs</subject><subject>Thrombocytopenia</subject><issn>1082-801X</issn><issn>1938-1166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkE1Lw0AQhoMoWKv_YcFzZL-SbLyV4hcU9FDBWxh3JyEl3dSdTcV_7xYFEcocZt6ZZ96BOclmolYmF6IsT1PNjcwNF2_n2QXRhnNelkrOsv45wMBGb8fhK_aWbhkQIVHvO7aHYUI2tszjJwYGHfpIbI-BJmJ2CiFpRhG8g-DoAFoImAzYDkI86Jc124XR4sHyMjtrYSC8-s3z7PX-br18zFfPD0_LxSrvpDExR-kMaCMKoXjpJEBZVRx1peu6RuDvbWFrw2UBaJ2ojXNoizZN2woLDrxS8-z6xzdd_piQYrMZp-DTyUZoxZUWdSX-qA4GbHrfjjGA3fZkm4XSSpdSVjJR-REq_QHT10aPbZ_a__ibI3wKh9veHln4Bi7igFc</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Weaver, Salome Bwayo</creator><creator>Moore, Clarence</creator><creator>Shah, Vicky</creator><creator>Serlemitsos-Day, Maritsa</creator><general>Intellisphere, LLC</general><general>MultiMedia Healthcare Inc</general><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7X7</scope><scope>7XB</scope><scope>883</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0F</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYYUZ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20130801</creationdate><title>Oral oncolytics: assessing value of newer agents versus current standards of care as part of PT processes</title><author>Weaver, Salome Bwayo ; Moore, Clarence ; Shah, Vicky ; Serlemitsos-Day, Maritsa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g288t-e2d8a48151306d2aa6770e474999ea0bf5c98025aecd198ddec5f749f7e50a073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anemia</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Blood platelets</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chromosomes</topic><topic>Drug dosages</topic><topic>Drug stores</topic><topic>Health aspects</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Medical treatment</topic><topic>Medicare</topic><topic>Mutation</topic><topic>Neutropenia</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pharmacy</topic><topic>Physicians</topic><topic>Prescription drugs</topic><topic>Thrombocytopenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weaver, Salome Bwayo</creatorcontrib><creatorcontrib>Moore, Clarence</creatorcontrib><creatorcontrib>Shah, Vicky</creatorcontrib><creatorcontrib>Serlemitsos-Day, Maritsa</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Trade & Industry (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Trade & Industry</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ABI/INFORM Collection China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Formulary (Cleveland, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weaver, Salome Bwayo</au><au>Moore, Clarence</au><au>Shah, Vicky</au><au>Serlemitsos-Day, Maritsa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral oncolytics: assessing value of newer agents versus current standards of care as part of PT processes</atitle><jtitle>Formulary (Cleveland, Ohio)</jtitle><date>2013-08-01</date><risdate>2013</risdate><volume>48</volume><issue>8</issue><spage>258</spage><pages>258-</pages><issn>1082-801X</issn><eissn>1938-1166</eissn><abstract>Oral oncolytics are relatively new to the field of cancer therapy. They currently make up about 25% of the oncology market and their use is continually expanding. The current insurance system is not efficiently equipped to handle the rapid expansion of oral oncolytics into the market, and the current insurance benefit design contributes significantly to access issues for patients. This article offers formulary decision makers information needed to evaluate newer oral oncolytic therapies compared with existing standards of care using guidelines from the National Comprehensive Cancer Network®. The oral agents discussed are limited to those introduced into the market since 2007. [PUBLICATION ABSTRACT]</abstract><cop>North Olmsted</cop><pub>Intellisphere, LLC</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1082-801X |
| ispartof | Formulary (Cleveland, Ohio), 2013-08, Vol.48 (8), p.258 |
| issn | 1082-801X 1938-1166 |
| language | eng |
| recordid | cdi_proquest_journals_1430341971 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Business Source Complete |
| subjects | Anemia Antimitotic agents Antineoplastic agents Blood platelets Cancer Cancer therapies Chromosomes Drug dosages Drug stores Health aspects Kinases Leukemia Medical treatment Medicare Mutation Neutropenia Oncology Patients Pharmacy Physicians Prescription drugs Thrombocytopenia |
| title | Oral oncolytics: assessing value of newer agents versus current standards of care as part of PT processes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T11%3A36%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20oncolytics:%20assessing%20value%20of%20newer%20agents%20versus%20current%20standards%20of%20care%20as%20part%20of%20PT%20processes&rft.jtitle=Formulary%20(Cleveland,%20Ohio)&rft.au=Weaver,%20Salome%20Bwayo&rft.date=2013-08-01&rft.volume=48&rft.issue=8&rft.spage=258&rft.pages=258-&rft.issn=1082-801X&rft.eissn=1938-1166&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA343462272%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1430341971&rft_id=info:pmid/&rft_galeid=A343462272&rfr_iscdi=true |